Alliance A021501 is a phase 2 randomized clinical trial that compares the efficacy of neoadjuvant modified FOLFIRINOX with or without hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas.1 The trial was led by the Alliance for Clinical Trials in Oncology with
What is Alliance A021806?
Alliance A021806 is a Phase III trial that aims to evaluate the efficacy of perioperative chemotherapy with mFOLFIRINOX in patients with resectable pancreatic cancer.1, 2 The study is actively accruing randomized controlled phase III trial evaluating the efficacy of perioperative chemotherapy with mFOLFIRINOX
Alliance A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer
Wake Forest Baptist Health will be joining the Alliance clinical trial A021806. This phase III that compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed